Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | DUT | P33316 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25877041 | 0.89 | ALDH1A1 (0.42) | HPGDSMN1; SMN2ALDH1A1HDAC2CACNA1H | |
| SCHEMBL19963737 | 0.87 | ALDH1A1 (0.37) | HPGDSMN1; SMN2ALDH1A1CACNA1HDUT | |
| SCHEMBL23594010 | 0.87 | ALDH1A1 (0.37) | HPGDSMN1; SMN2ALDH1A1CACNA1HDUT | |
| SCHEMBL19698420 | 0.84 | SIGMAR1 (0.39) | HPGDSMN1; SMN2ALDH1A1CACNA1HDUT | |
| SCHEMBL18272838 | 0.83 | CACNA1H (0.41) | HPGDSMN1; SMN2ALDH1A1CACNA1HDUT | |
| SCHEMBL20469923 | 0.83 | CA12 (0.38) | HPGDSMN1; SMN2ALDH1A1HDAC2CACNA1H | |
| SCHEMBL20317401 | 0.82 | HPGD (0.40) | HPGDSMN1; SMN2ALDH1A1HDAC2DUT | |
| SCHEMBL22751820 | 0.82 | ALDH1A1 (0.41) | HPGDSMN1; SMN2ALDH1A1HDAC2DUT | |
| SCHEMBL18272857 | 0.82 | CACNA1H (0.40) | HPGDSMN1; SMN2ALDH1A1CACNA1HTSHR | |
| SCHEMBL18272803 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20210332065-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-28 | — | — | US | disclosed |
| US-20210315904-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | HPGD 2573/4885SMN1; SMN2 2977/4885ALDH1A1 4140/4885 |
| US-20220175722-A1 | DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) | FGFR2, FGF2, FGFR1 | HPGD 4494/4885SMN1; SMN2 766/4885ALDH1A1 2103/4885 |
| US-20210315904-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | HPGD 913/4885SMN1; SMN2 1293/4885ALDH1A1 3743/4885 |
| US-20230133538-A1 | TARGETED DEGRADERS OF ABERRANT TAU BASED ON THE PET TRACER PBB3 | MAPT, PSEN1, PSEN2 | HPGD 4815/4885SMN1; SMN2 699/4885ALDH1A1 3938/4885 |
| US-20210332065-A1 | BCL-2 INHIBITORS | BCL2L10, BCL2, BCL2L11 | HPGD 913/4885SMN1; SMN2 1293/4885ALDH1A1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.